Multi-cancer early detection (MCED) assays represent a new paradigm in cancer screening with the potential to deliver on the promise of earlier detection of many cancers with a single test. This technology is quickly moving into the mainstream,  which means more patients will be asking about it. In this webinar,  we will explore the results of the Pathfinder Study, which evaluated the Galleri test, and we'll hear how practitioners are implementing this cutting-edge technology into their practices.